HOME >> MEDICINE >> NEWS
Jefferson scientists find that drug-eluting stents are disappointing in bypass grafts -- sometimes

(PHILADELPHIA) -- While drug-eluting stents are effective in keeping open bypassed heart veins that arent too diffuse (filled with cholesterol plaque), a new study by cardiologists at Jefferson Medical College shows that they fare less well in keeping open bypassed veins with longer blockages. The researchers suggest that doctors think twice before inserting the drug-coated stents in such extensively diseased bypassed grafts.

The researchers looked at the success of drug-eluting stents in bypassed vein grafts and found that long-term success was dependent on the healthiness of the vessel. Lead researcher Nicholas J. Ruggiero II, M.D., a fellow in cardiovascular diseases, will present the results at the American College of Cardiologys 56th Annual Scientific Session on Monday, March 26, from 4 to 4:50 pm. (Abstract 916-214).

Seventy patients--61 men and nine women with a mean age of 70 years--were studied. Twenty eight (40 percent) of the patients had diabetes. The researchers divided the patients into those with focal disease (less than 30 millimeters of disease or fewer than three blockages in one vessel) or diffuse (extensive) disease (more than 30 millimeters of disease or three or more lesions in a single bypass).

Focal disease is considered to be less of a problem in the veins of patients who have undergone heart bypass surgery. Diffuse disease means that the artery is much more clogged and therefore at greater risk of re-clogging.

Thirty nine percent of the patients had diffuse disease. After one year, the researchers found that 84 percent of these patients were free of clinical restenosis (re-clogging) or disease in the drug-eluted stent bypasses. In patients with focal blockage, only three percent needed an additional procedure to treat restenosis after one year. In contrast, in patients with diffuse disease, 37 percent needed additional procedures to treat restenosis.

"To date, drug-eluting stents havent
'"/>

Contact: Nan Myers
nan.myers@jefferson.edu
215-955-6300
Thomas Jefferson University
26-Mar-2007


Page: 1 2

Related medicine news :

1. Fat protein cuts blood vessel inflammation, may help heart, Jefferson scientists find
2. Jefferson pharmacologist says biomarker discovery bodes well for better cancer diagnostics
3. Jefferson immunology researchers show blood-brain barrier damage could affect MS severity
4. Jefferson scientists find that plavix appears to be safe during and after heart bypass
5. Treatment of in-hospital cardiac patients is focus of Jefferson University presentations
6. Empathy skills must be given a high priority in medical education, says Jefferson author
7. Natural, soy-based substance might help fight MS, Jefferson neuroscientists find
8. Blood pressure drugs could help halt pancreatic cancer spread, Jefferson researchers find
9. Obesity tied to higher risk of complications in spinal surgery, Jefferson neurosurgeon finds
10. Jefferson Orthopaedic surgeons leading international study of timing of spinal surgery
11. Jefferson scientists find boosting protein levels staves off heart failure

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/16/2019)... ... November 15, 2019 , ... ... impairment, has announced the Best Memory Care Facilities in Medford, Oregon. The guide ... and amenities. , According to the Alzheimer’s Association , 5.6 million ...
(Date:11/16/2019)... ... November 16, 2019 , ... Uniform Advantage (UA), ... nation’s largest faith-based health systems, as it underwent its brand transition from Adventist ... from product selection to fitting events to uniform delivery. The scope of the ...
(Date:11/15/2019)... GARDEN CITY, N.Y. (PRWEB) , ... November 15, ... ... a list of over 100 employers in Newsday’s Top Long Island Workplaces for ... and empowered. , During the selection process, Newsday worked in partnership with ...
(Date:11/14/2019)... ... November 14, 2019 , ... ... specifically targeted for Roche cobas® and Roche COBAS INTEGRA® analyzers, Order No. ... (C3), Complement C4 (C4), Immunoglobulin A (IGA), Immunoglobulin G (IGG), Immunoglobulin M ...
(Date:11/14/2019)... ... November 14, 2019 , ... ... Administration (FDA) has granted acceptance to file status of its application for the ... in the disease neurofibromatosis type one (NF1). The FDA’s acceptance of the application ...
Breaking Medicine News(10 mins):
(Date:11/19/2019)... ... November 19, 2019 , ... There are just some of ... stay healthy and pain-free. Chiropractic is a healthcare field that focuses primarily on ... effects of these conditions on the body’s general health. , At Kosterman ...
(Date:11/19/2019)... MIAMI (PRWEB) , ... November 19, 2019 , ... As ... customers, Capillus, LLC has undergone a name change. The Florida company is now Curallux, ... medical device and cosmetic industries. The new name, “Curallux”, stems from Latin words for ...
(Date:11/19/2019)... PITTSBURGH (PRWEB) , ... November 19, 2019 , ... ... and management of hemophilia, which aims to ensure that members receive hemophilia drugs ... fraud that increases costs. Beginning in January of 2020, Highmark members will receive ...
Breaking Medicine Technology:
Cached News: